#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ln.	re	ann	lication	ot.
		avv	uvation	UI.

Hong Chen

Application No.:

I I a manusiale

Group No.:

N/A

Filed:

Herewith

Examiner:

N/A

For:

HUMAN GLUCOSE-6-PHOSPHATASE MOLECULES AND USES THEREOF

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. This submission accompanies the new application being filed concurrently herewith

#### IDENTIFICATION OF PERSON MAKING STATEMENT

2. 1,	Kerri Pollard Schray		
	(type or print name of	of person si	gning below)
st	tate the following:		
	CERTIFICATION UNDER 37	C.F.R. SECT	ΓΙΟΝS 1.8(a) and 1.10*
1 hereb	by certify that, on the date shown below, this corresponde	ence is being:	
×	MA deposited with the United States Postal Service in an Commissioner for Patents, P.O. Box 1450, Alexandr 37 C.F.R. SECTION 1.8(a)		
	with sufficient postage as first class mail.	×	as "Express Mail Post Office to Addressee" Mailing Label No. <u>EL992152698US</u>
		SMISSION	
	transmitted by facsimile to the Patent and Trademark	Office.	from Ang
Date:	<u>September 16, 2003</u>		Hunziker or print name of person certifying)

\*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 4)

#### ITEMS BEING SUBMITTED

3.	Submitte	d here	with	is/are:

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. ( ) An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. [] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. (X) Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:	Hong Chen		
Application No.:	09/874,132	Group No.:	1652
Filed:	June 24, 2001	Examiner:	Pak, Yong D.
For:	HUMAN GLUCOSE-6-PHOSPH	ATASE MOLE	CULES AND USES THEREOF

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form	"Sequence Identifier"
(other application)	(this application)

E.	[X]	Α	statement	that	the	content	of	each	"Sequence	Listing"	submitted	and	each	computer
	• •	re	adable copy	y are	the s	same, as	req	uired	in 37 C.F.R.	Section	1.821(f).			

( )	Because the statement is not made by a person registered to practice before the Office	ce.
` ^	the Statement is verified as required in 37 C.F.R. Section 1.821(b).	

4.

5.

F. ( )	Because this submission 1.821(g), a statement the	on is made in fulfilling the requirement und at the submission includes no new matter.	der 37 C.F.R. Section
		tent is not made by a person registered to practified, as required in 37 C.F.R. Section 1.821(g)	
	AND COMP	MENT THAT "SEQUENCE LISTING" UTER READABLE COPY ARE THE SAM PERS SUBMITTED INCLUDES NO NEW N	
4. I hereb	by state:		
A. (X)	Each computer readable be transferred from app it is indicated to relate.	e form submitted in this application, including the licant's other application, is the same as the "Seq	hose forms requested to quence Listing" to which
B. [X]	All papers accompanying other application, introduced in the second seco	ng this submission, or for which a request for t duce no new matter.	ransfer from applicants
		EXTENSION OF TERM	
5. The pro	oceedings herein are for a	patent application and the provisions of 37 C.F.I	R. Section 1.136 apply.
	Applicant petitions for	an extension of time under 37 C.F.R. Section for the total number of months checked below:	
E:	xtension	Fee for other than	Fee for
<u>(n</u>	nonths)	small entity	small entity
(	) one month	\$ 110.00	\$ 55.00
_	two months	\$ 390.00	\$ 195.00
(	) three months	\$ 890.00	\$ 445.00
(	) four months	\$1,390.00	\$ 695.00
			Fee \$0.00
If an addit	ional extension of time is	required, please consider this a petition therefor	
	( ) An extension for	months has already been secured, and the s deducted from the total fee due for the total mo	e fee paid therefor of onths of extension
		Extension fee due with thi	is request \$0.00

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

r	LE PAYMENT
6. ( ) Attached is a check in the sum of \$	·
[ ] Charge Account No. 501668 the s A duplicate of this transmittal is attach	
FE	E DEFICIENCY
8. [X] If any additional extension and/or fee	is required, charge Account No. 501668.
September 16, 2003	MILLENNIUM PHARMACEUTICALS, INC.
	By Kartell Ses
	Kerri Pollard Schray
	Attorney/Agent for Applicant
	Registration No. 47,066
	75 Sidney Street
	Cambridge, MA 02139
	Telephone – (617) 551-3676
	Facsimile – (617) 551-8820